# Semaglutide

Canonical source: https://retacompare.com/encyclopedia/semaglutide

Long-acting GLP-1 receptor agonist. Glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, central satiety signaling.

Reference facts

Also known asOzempic, Wegovy, RybelsusCategoryGLP-1 & MetabolicMechanism of actionLong-acting GLP-1 receptor agonist. Glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, central satiety signaling.TargetsGLP-1RIndications under research or approvedType 2 Diabetes, Obesity, Cardiovascular Risk Reduction (T2D + CVD)Regulatory status (reference entry)FDA-approved (Ozempic 2017, Rybelsus 2019, Wegovy 2021)Half-life~165 hours (~7 days)SequenceHXEGTFTSDVSSYLEGQAAKEFIAWLVRGRGSequence notes31-residue GLP-1 analog. Aib at position 2 (X), C18 fatty diacid linker at Lys26, Arg substitution at position 34.Molecular weight (Da)4114PDB accession4ZGMOriginator / sponsorNovo NordiskFirst reported2012OriginDeveloped by Novo Nordisk by extending the half-life of Liraglutide via a longer fatty diacid linker.
    Primary References

STEP-1 — Semaglutide for obesity, NEJM 2021

SUSTAIN-6 — Cardiovascular outcomes, NEJM 2016

FDA Wegovy label


    Explore research articles about Semaglutide


    This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.

## Sources

- STEP-1 — Semaglutide for obesity, NEJM 2021: https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
- SUSTAIN-6 — Cardiovascular outcomes, NEJM 2016: https://www.nejm.org/doi/full/10.1056/NEJMoa1607141
- FDA Wegovy label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf